20.500.12556/RUL-182344 Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency the FAIR-HFpEF trial Background and aims: Evidence is lacking that correcting iron deficiency (ID) has clinically important benefits for patients with heart failure with preserved ejection fraction (HFpEF). Methods: FAIR-HFpEF was a multicentre, randomized, double-blind trial designed to compare intravenous ferric carboxymaltose (FCM) with placebo (saline) in 200 patients with symptomatic HFpEF and ID (serum ferritin < 100 ng/mL or ferritin 100-299 ng/mL with transferrin saturation < 20%). The primary endpoint was change in 6-min walking test distance (6MWTD) from baseline to week 24. Secondary endpoints included changes in New York Heart Association class, patient global assessment, and health-related quality of life (QoL). Results: The trial was stopped because of slow recruitment after 39 patients had been included (median age 80 years, 62% women). The change in 6MWTD from baseline to week 24 was greater for those assigned to FCM compared to placebo [least square mean difference 49 m, 95% confidence interval (CI) 5-93; P = .029]. Changes in secondary endpoints were not significantly different between groups. The total number of adverse events (76 vs. 114) and serious adverse events (5 vs. 19; rate ratio 0.27, 95% CI 0.07-0.96; P = .043) was lower with FCM than placebo. Conclusions: In patients with HFpEF and markers of ID, intravenous FCM improved 6MWTD and was associated with fewer serious adverse events. However, the trial lacked sufficient power to identify or refute effects on symptoms or QoL. The potential benefits of intravenous iron in HFpEF with ID should be investigated further in a larger cohort. exercise capacity heart failure iron deficiency preserved ejection fraction zmogljivost pri telesni vadbi srčno popuščanje pomanjkanje železa ohranjena iztisna funkcija true false true Angleški jezik Slovenski jezik Članek v reviji 2026-05-08 04:51:17 2026-05-08 09:20:10 2026-10-07 12:04:21 0000-00-00 00:00:00 2024 0 0 Str. 3789-3800 iss. 37 Vol. 45 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.1 0195-668X 10.1093/eurheartj/ehae479 224962051 RAZ_Haehling_Stephan_2024.pdf RAZ_Haehling_Stephan_2024.pdf 1 88C571FEEE0E299223269F5E8378E480 b450d9398864642fd4d1b0996060edf613ee97343e407098b5fda625588c2ef0 b91cf4d6-4aae-11f1-b0ab-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=233530 https://academic.oup.com/eurheartj/article/45/37/3789/7741587?login=false 1 825038bc-4a88-11f1-b0ab-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=233511 Medicinska fakulteta 0 0 0